Search

Your search keyword '"Algara, Manel"' showing total 25 results
Start Over Author "Algara, Manel"
25 results on '"Algara, Manel"'

4. Diagnosis and locoregional treatment of patients with breast cancer during the COVID-19 pandemic

Author

Pardo, Ricardo, Algara, Manel, Montero-Fernández, María Angeles, Sanz, Xavier, Vernet, Mar, Rodríguez, Nuria, Andrés-Luna, Rogelio, Piñero, Antoni, Ciérvide, Raquel, Córdoba, Raúl, Dave, Rajiv V., Montero, Ángel, Osorio, Irene, Argudo, Nuria, Salido, Sergio, Bernar, Juan, Pritchard, Susan, Alves, Natalia Frade, Nicolau, Pau, Orihuela, Pilar, and Jiménez, Marta

Published
2020
Full Text
View/download PDF

6. Linfoma anaplásico de células grandes asociado a implantes mamarios. Documento de consenso (I): epidemiología, patogenia, clínica y diagnóstico

Author

Acea, B., Albi, B., Albi, M., Andrés-Luna, R., Ara, C., Arranz, M., Caba, M., Camps, J., Carcamo, C., Ciérvide, R., Comin, L., Cordeiro, P., de Castro, G., Delgado, M., Durán Poveda, M., Estelles, N., Estrada, N., Fernández, E., Fuster, G., García-Foncillas, J., García, I., García Mur, C., Garcia Pardo, L., Gil Olarte, M.A., Gómez, M.T., González, A., Gutierrez, I., Hernanz, F., Izarzugaza, Y., Jimeno, J., Lobo, F., Martínez, D., Martínez, M., Martínez, R., Matei, P., Masià, J., Menjón, S., Murillo, J., Orihuela, P., Osorio, I., Lillo, A. Peña y, Pérez, S., Pinardo, A., Piris, M.A., Pla, M.J., Ramón y Cajal, T., Ramos, M., Ramos, T., Rivas, S., Rodriguez, I., Rodriguez, N., Romero, C., Rojo, F., Sanroman, J.M., Sanz, J., Salvatierra, V., Salido, S., Sánchez, J.I., Serra, J.M., Serrano, C., Socorro, M., Tejerina, Alejandro, Tejerina, Antonio, Treserra, F., Valadas, G., Vernet, M., Vega, V., Vidal, S., Zarain, L., Pardo, Ricardo, Quintana, Rosa, Piñero, Antonio, Vázquez, Carlos, Cabañas, Jacobo, Martínez Regueira, Fernando, Bernet, Laia, Rioja, María Eugenia, Rabadán, Lorenzo, Barriga, Raquel, Mallent, José, Urruticoetxea, Ander, Algara, Manel, Montero, Ángel, Palomo, Teresa, Llamas, Pilar, and Córdoba, Raúl

Published
2019
Full Text
View/download PDF

7. Linfoma anaplásico de células grandes asociado a implantes mamarios. Documento de consenso parte II: estadificación, tratamiento, pronóstico y seguimiento

Author

Acea, B., Albi, B., Albi, M., Andrés-Luna, R., Ara, C., Arranz, M., Caba, M., Camps, J., Carcamo, C., Ciérvide, R., Comin, L., Cordeiro, P., De Castro, G., Delgado, M., Durán Poveda, M., Estelles, N., Estrada, N., Fernández, E., Fuster, G., García-Foncillas, J., García, I., García Mur, C., García Pardo, L., Gil Olarte, M.A., Gómez, M.T., González, A., Gutierrez, I., Hernanz, F., Izarzugaza, Y., Jimeno, J., Lobo, F., Martínez, D., Martínez, M., Martínez, R., Matei, P., Masià, J., Menjón, S., Murillo, J., Orihuela, P., Osorio, I., Peña y Lillo, A., Pérez, S., Pinardo, A., Piris, M.A., Pla, M.J., Ramón y Cajal, T., Ramos, M., Ramos, T., Rivas, S., Rodriguez, I., Rodríguez, N., Romero, C., Rojo, F., Sanromán, J.M., Sanz, J., Salvatierra, V., Salido, S., Sánchez, J.I., Serra, J.M., Serrano, C., Socorro, M., Alejandro, Tejerina, Antonio, Tejerina, Treserra, F., Valadas, G., Vernet, M., Vega, V., Vidal, S., Zarain, L., Pardo, Ricardo, Quintana, Rosa, Piñero, Antonio, Vázquez, Carlos, Cabañas, Jacobo, Martínez Regueira, Fernando, Palomo, Teresa, Llamas, Pilar, Córdoba, Raúl, Rabadán, Lorenzo, Barriga, Raquel, Mallent, José, Urruticoetxea, Ander, Algara, Manel, Montero, Ángel, Bernet, Laia, and Rioja, María Eugenia

Published
2019
Full Text
View/download PDF

13. Effect of Low-Dose Radiotherapy on the Circulating Levels of Paraoxonase-1-Related Variables and Markers of Inflammation in Patients with COVID-19 Pneumonia

Author

Rodríguez-Tomàs, Elisabet, primary, Acosta, Johana C., additional, Torres-Royo, Laura, additional, De Febrer, Gabriel, additional, Baiges-Gaya, Gerard, additional, Castañé, Helena, additional, Jiménez, Andrea, additional, Vasco, Carlos, additional, Araguas, Pablo, additional, Gómez, Junior, additional, Malave, Bárbara, additional, Árquez, Miguel, additional, Calderón, David, additional, Piqué, Berta, additional, Algara, Manel, additional, Montero, Ángel, additional, Simó, Josep M., additional, Gabaldó-Barrios, Xavier, additional, Sabater, Sebastià, additional, Camps, Jordi, additional, Joven, Jorge, additional, and Arenas, Meritxell, additional

Published
2022
Full Text
View/download PDF

14. Effect of Low-Dose Radiotherapy on the Circulating Levels of Paraoxonase-1-Related Variables and Markers of Inflammation in Patients with COVID-19 Pneumonia

Author

Universitat Rovira i Virgili, Rodriguez-Tomas, Elisabet; Acosta, Johana C.; Torres-Royo, Laura; De Febrer, Gabriel; Baiges-Gaya, Gerard; Castane, Helena; Jimenez, Andrea; Vasco, Carlos; Araguas, Pablo; Gomez, Junior; Malave, Barbara; Arquez, Miguel; Calderon, David; Pique, Berta; Algara, Manel; Montero, Angel; Simo, Josep M.; Gabaldo-Barrios, Xavier; Sabater, Sebastia; Camps, Jordi; Joven, Jorge; Arenas, Meritxell, Universitat Rovira i Virgili, and Rodriguez-Tomas, Elisabet; Acosta, Johana C.; Torres-Royo, Laura; De Febrer, Gabriel; Baiges-Gaya, Gerard; Castane, Helena; Jimenez, Andrea; Vasco, Carlos; Araguas, Pablo; Gomez, Junior; Malave, Barbara; Arquez, Miguel; Calderon, David; Pique, Berta; Algara, Manel; Montero, Angel; Simo, Josep M.; Gabaldo-Barrios, Xavier; Sabater, Sebastia; Camps, Jordi; Joven, Jorge; Arenas, Meritxell

Abstract

The aim of our study was to investigate the changes produced by low-dose radiotherapy (LDRT) in the circulating levels of the antioxidant enzyme paraoxonase-1 (PON1) and inflammatory markers in patients with COVID-19 pneumonia treated with LDRT and their interactions with clinical and radiological changes. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 30 patients treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as PON1-related variables, cytokines, and radiological parameters were analyzed before LDRT, at 24 h, and 1 week after treatment. Twenty-five patients (83.3%) survived 1 week after LDRT. Respiratory function and radiological images improved in survivors. Twenty-four hours after LDRT, PON1 concentration significantly decreased, while transforming growth factor beta 1 (TGF-beta 1) increased with respect to baseline. One week after LDRT, patients had increased PON1 activities and lower PON1 and TGF-beta 1 concentrations compared with 24 h after LDRT, PON1 specific activity increased, lactate dehydrogenase (LDH), and C-reactive protein (CRP) decreased, and CD4+ and CD8+ cells increased after one week. Our results highlight the benefit of LDRT in patients with COVID-19 pneumonia and it might be mediated, at least in part, by an increase in serum PON1 activity at one week and an increase in TGF-beta 1 concentrations at 24 h.

Published
2022

15. Abstract PD7-09: Safety of conservative surgery with accelerated partial breast re-irradiation for isolated ipsilateral breast cancer recurrence regardless of immunohistochemical subtype. A multicentric prospective study

Author

Espinosa-Bravo, Martin, primary, Lopez, Victoria Reyes, additional, Comas, Clara Morales, additional, Déniz, Joaquín Rivero, additional, de La Torre Fernández de Vega, Javier, additional, Roselló, Irene Vives, additional, Raber, Christian Sisó, additional, Gonzalez, Manuel Altabas, additional, Marin, Alexandra Giraldo, additional, Alonso, Inma, additional, Argudo, Nuria, additional, Nicolau, Pau, additional, Algara, Manel, additional, Sanz, Xavier, additional, Caparrós, Xavier, additional, Oses, Gabriela, additional, Saez, Jordi, additional, Vernet-Tomas, María, additional, and Mollà, Meritxell, additional

Published
2022
Full Text
View/download PDF

16. Profesionales entrevistados

Author

Acea, Benigno, primary, Alba, Emilio, additional, Algara, Manel, additional, Arcusa, Àngels, additional, Aznar, Ismael, additional, Barón, Francisco J, additional, Boceta, Jaime, additional, Brunet, Joan, additional, Bustamante, Manolo, additional, Caballero, Pastora, additional, Castillo, Isabel, additional, Collet, Imma, additional, de la Cruz, Luis, additional, Ramón Delgado, Juan, additional, Díaz-Rubio, Eduardo, additional, Espin, Eloy, additional, Expósito, José, additional, Ferro, Tàrsila, additional, Antonio Ferrón, José, additional, Flechilla, Mar, additional, Germà, Josep R., additional, Gómez, Dulce, additional, Guedea, Ferran, additional, Guerra, Juan A., additional, de las Heras, Manuel, additional, Herruzo, Ismael, additional, Lluch, Ana, additional, Mariscal, Antonio, additional, Martínez Agulló, Ángel, additional, Miranda, Pilar, additional, José Ortiz, Maria, additional, Palacios, José, additional, Paz-Ares, Luis, additional, Pereira, Fernando, additional, Porta, Josep, additional, Saigí, Eugeni, additional, Tormo, Alejandro, additional, Torres, Antonio J, additional, and Veiras, Camilo, additional

Published
2011
Full Text
View/download PDF

17. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain

Author

Martín, Miguel Ángel, Guerrero‐Zotano, Ángel, Montero, Ángel, Jara, Carlos, Filipovich, Elena, Rojo-Todo, Federico, Moreno, Fernando, Alés, José Enrique, Chacón López‑Muñiz, J. I., Cruz Jurado, Josefina, Giménez, Julia, Cruz Merino, L. de la, Algara, Manel, Santisteban, Marta, López-Tarruella, S., Martín, Miguel Ángel, Guerrero‐Zotano, Ángel, Montero, Ángel, Jara, Carlos, Filipovich, Elena, Rojo-Todo, Federico, Moreno, Fernando, Alés, José Enrique, Chacón López‑Muñiz, J. I., Cruz Jurado, Josefina, Giménez, Julia, Cruz Merino, L. de la, Algara, Manel, Santisteban, Marta, and López-Tarruella, S.

Abstract

Breast cancer (BC) is the most common cancer in women in Spain. During the COVID‐19 pandemic caused by the SARS‐CoV‐2 virus, patients with BC still require timely treatment and follow‐up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in‐hospital visit to minimize pandemic‐associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID‐19 pandemic. Owing to the lack of evidence about COVID‐19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing.

Published
2020

20. Linfoma anaplásico de células grandes asociado a implantes mamarios. Documento de consenso parte II: estadificación, tratamiento, pronóstico y seguimiento

Author

Pardo, Ricardo, primary, Quintana, Rosa, additional, Piñero, Antonio, additional, Vázquez, Carlos, additional, Cabañas, Jacobo, additional, Martínez Regueira, Fernando, additional, Palomo, Teresa, additional, Llamas, Pilar, additional, Córdoba, Raúl, additional, Rabadán, Lorenzo, additional, Barriga, Raquel, additional, Mallent, José, additional, Urruticoetxea, Ander, additional, Algara, Manel, additional, Montero, Ángel, additional, Bernet, Laia, additional, Rioja, María Eugenia, additional, Acea, B., additional, Albi, B., additional, Albi, M., additional, Andrés-Luna, R., additional, Ara, C., additional, Arranz, M., additional, Caba, M., additional, Camps, J., additional, Carcamo, C., additional, Ciérvide, R., additional, Comin, L., additional, Cordeiro, P., additional, De Castro, G., additional, Delgado, M., additional, Durán Poveda, M., additional, Estelles, N., additional, Estrada, N., additional, Fernández, E., additional, Fuster, G., additional, García-Foncillas, J., additional, García, I., additional, García Mur, C., additional, García Pardo, L., additional, Gil Olarte, M.A., additional, Gómez, M.T., additional, González, A., additional, Gutierrez, I., additional, Hernanz, F., additional, Izarzugaza, Y., additional, Jimeno, J., additional, Lobo, F., additional, Martínez, D., additional, Martínez, M., additional, Martínez, R., additional, Matei, P., additional, Masià, J., additional, Menjón, S., additional, Murillo, J., additional, Orihuela, P., additional, Osorio, I., additional, Peña y Lillo, A., additional, Pérez, S., additional, Pinardo, A., additional, Piris, M.A., additional, Pla, M.J., additional, Ramón y Cajal, T., additional, Ramos, M., additional, Ramos, T., additional, Rivas, S., additional, Rodriguez, I., additional, Rodríguez, N., additional, Romero, C., additional, Rojo, F., additional, Sanromán, J.M., additional, Sanz, J., additional, Salvatierra, V., additional, Salido, S., additional, Sánchez, J.I., additional, Serra, J.M., additional, Serrano, C., additional, Socorro, M., additional, Alejandro, Tejerina, additional, Antonio, Tejerina, additional, Treserra, F., additional, Valadas, G., additional, Vernet, M., additional, Vega, V., additional, Vidal, S., additional, and Zarain, L., additional

Published
2019
Full Text
View/download PDF

21. Linfoma anaplásico de células grandes asociado a implantes mamarios. Documento de consenso (I): epidemiología, patogenia, clínica y diagnóstico

Author

Pardo, Ricardo, primary, Quintana, Rosa, additional, Piñero, Antonio, additional, Vázquez, Carlos, additional, Cabañas, Jacobo, additional, Martínez Regueira, Fernando, additional, Bernet, Laia, additional, Rioja, María Eugenia, additional, Rabadán, Lorenzo, additional, Barriga, Raquel, additional, Mallent, José, additional, Urruticoetxea, Ander, additional, Algara, Manel, additional, Montero, Ángel, additional, Palomo, Teresa, additional, Llamas, Pilar, additional, Córdoba, Raúl, additional, Acea, B., additional, Albi, B., additional, Albi, M., additional, Andrés-Luna, R., additional, Ara, C., additional, Arranz, M., additional, Caba, M., additional, Camps, J., additional, Carcamo, C., additional, Ciérvide, R., additional, Comin, L., additional, Cordeiro, P., additional, de Castro, G., additional, Delgado, M., additional, Durán Poveda, M., additional, Estelles, N., additional, Estrada, N., additional, Fernández, E., additional, Fuster, G., additional, García-Foncillas, J., additional, García, I., additional, García Mur, C., additional, Garcia Pardo, L., additional, Gil Olarte, M.A., additional, Gómez, M.T., additional, González, A., additional, Gutierrez, I., additional, Hernanz, F., additional, Izarzugaza, Y., additional, Jimeno, J., additional, Lobo, F., additional, Martínez, D., additional, Martínez, M., additional, Martínez, R., additional, Matei, P., additional, Masià, J., additional, Menjón, S., additional, Murillo, J., additional, Orihuela, P., additional, Osorio, I., additional, Lillo, A. Peña y, additional, Pérez, S., additional, Pinardo, A., additional, Piris, M.A., additional, Pla, M.J., additional, Ramón y Cajal, T., additional, Ramos, M., additional, Ramos, T., additional, Rivas, S., additional, Rodriguez, I., additional, Rodriguez, N., additional, Romero, C., additional, Rojo, F., additional, Sanroman, J.M., additional, Sanz, J., additional, Salvatierra, V., additional, Salido, S., additional, Sánchez, J.I., additional, Serra, J.M., additional, Serrano, C., additional, Socorro, M., additional, Tejerina, Alejandro, additional, Tejerina, Antonio, additional, Treserra, F., additional, Valadas, G., additional, Vernet, M., additional, Vega, V., additional, Vidal, S., additional, and Zarain, L., additional

Published
2019
Full Text
View/download PDF

22. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

Author

Rodríguez, A., Arenas, M., Lara, P. C., López-Torrecilla, J., Algara, Manel, Conde del Campo, Ana, Pérez-Montero, H., Muñoz, J. L., Peleteiro, P., Pérez-Calatayud, M. J., Contreras, Julia, Ferrer, C., Rodríguez, A., Arenas, M., Lara, P. C., López-Torrecilla, J., Algara, Manel, Conde del Campo, Ana, Pérez-Montero, H., Muñoz, J. L., Peleteiro, P., Pérez-Calatayud, M. J., Contreras, Julia, and Ferrer, C.

Abstract

[Aim] Radiation oncology services in Spain are undergoing a process of technical modernization, but—in a context of increasing demand by an ageing population—it is unclear whether there are enough radiation oncologists to staff the newly equipped units. This study aims to assess the number of specialists working in radiation oncology services in Spain relative to current and future needs. [Materials and methods] In the second half of 2017, the Commission on Infrastructures of the Spanish Society for Radiation Oncology (SEOR) sent a questionnaire on radiation oncology staff to the heads of all 122 public (n = 76, 62%) and private (n = 46, 38%) radiation oncology services in Spain. Data collected were the number of professionals, their position, and their year of birth for specialists and residents in each service. In the descriptive analysis, for continuous variables we calculated means, standard deviations and ranges for each Spanish region and work post. For qualitative variables, we constructed frequency tables. All analyses were performed with R statistical software, version 3.5.1. [Results]The survey response rate was 100% among service heads across all 122 centers. The total number of radiation oncologists working in these centers is 721, or 15.4 per million population, with considerable variations between regions. Given the national recommendations to have 20 radiation oncologists per million population, there is currently a deficit of 204 specialists. If the 163 upcoming retirements are also taken into account, there will be 367 fewer radiation oncologists than required to meet the 25% increase in indications for radiotherapy projected for 2025. [Conclusions] The classic model for calculating staff needs based on the number of treatments is outdated, and recommendations should be revised to reflect the current reality. A new model should integrate the most complex technological advances and emerging plans in radiotherapy, without neglecting the other activiti

Published
2019

23. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID‐19 Pandemic in Spain.

Author

Martin, Miguel, Guerrero‐Zotano, Angel, Montero, Ángel, Jara, Carlos, Filipovich, Elena, Rojo, Federico, Moreno, Fernando, García‐Sáenz, Jose Ángel, Alés, Jose Enrique, Chacón, José Ignacio, Cruz, Josefina, Gimenez, Julia, Cruz‐Merino, Luis, Algara, Manel, Santisteban, Marta, and Tarruella, Sara López

Subjects
BREAST tumor treatment, CANCER chemotherapy, CANCER patient psychology, COMBINED modality therapy, PREVENTION of communicable diseases, MEDICAL protocols, RADIOTHERAPY, OPERATIVE surgery, WOMEN'S health
Abstract

Breast cancer (BC) is the most common cancer in women in Spain. During the COVID‐19 pandemic caused by the SARS‐CoV‐2 virus, patients with BC still require timely treatment and follow‐up; however, hospitals are overwhelmed with infected patients and, if exposed, patients with BC are at higher risk for infection and serious complications if infected. Thus, health care providers need to evaluate each BC treatment and in‐hospital visit to minimize pandemic‐associated risks while maintaining adequate treatment efficacy. Here we present a set of guidelines regarding available options for BC patient management and treatment by BC subtype in the context of the COVID‐19 pandemic. Owing to the lack of evidence about COVID‐19 infection, these recommendations are mainly based on expert opinion, medical organizations' and societies' recommendations, and some published evidence. We consider this a useful tool to facilitate medical decision making in this health crisis situation we are facing. Implications for Practice: This work presents a set of guidelines regarding available options for breast cancer (BC) patient management and treatment by BC subtype in the context of the COVID‐19 pandemic. Owing to the suddenness of this health crisis, specialists have to make decisions with little evidence at hand. Thus, these expert guidelines may be a useful tool to facilitate medical decision making in the context of a worldwide pandemic with no resources to spare. Guidelines for breast cancer patient management in the context of the COVID‐19 pandemic are suggested, which may help clinicians and patients to facilitate medical decision making. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Whole-breast hypofractionated IMRT and brachytherapy boost after conservative surgery for breast cancer: Early results of a prospective non-randomised trial.

Author

Guix, Benjamin, primary, Garcia, Ivan, additional, Guix, Ines, additional, Lejarcegui, Juan Antonio, additional, Tello, Jose Ignacio, additional, Prats, Miquel, additional, Quinzaños, Luis, additional, Mases, Joel, additional, Algara, Manel, additional, Monne, Josep Maria Sole, additional, and Guix, Teresa, additional

Published
2015
Full Text
View/download PDF

25. Challenges in assessing national radiotherapy costs: application of the ESTRO-HERO model in Spain.

Author

Corral J, Algara M, Muñoz-Montplet C, Eraso A, Giralt J, Defourny N, Lievens Y, and Borras JM

Subjects
Humans, Spain, Health Care Costs statistics & numerical data, Neoplasms radiotherapy, Neoplasms economics, Radiotherapy economics, Radiotherapy statistics & numerical data
Abstract

Background and Purpose: The aim was to estimate the cost of the external beam radiotherapy (EBRT) in public health care centers in Catalonia (Spain), according to the ESTRO-HERO costing model for 2018., Materials and Methods: Personnel, equipment, and activity data from 2018 from the 11 RT centers were used, incorporating European mean values adapted to the Catalan context. Secondly, EBRT costs were estimated, incorporating 2023 fractionation technique and scheme usage percentages. Finally, complementary estimates were included: complementary planning examinations, stereotactic body radiation therapy (SBRT) fiducial markers, and hospital overhead costs., Results: In 2018, EBRT cost was estimated at EUR 42.2 M for all patients in the region. Directly related treatment activities represented 69.0% of the total cost, while support and non-directly related EBRT activities accounted for 20.2 and 10.8%, respectively. Mean radical treatment cost varied from €1714 (leukemia) to €4,645 (pancreas), and for palliative intent, from €938 (bone metastases) to €1753 (brain metastases). According to the technique used, costs ranged from €1,475 (3D conformal) to €3,608 (rotational IMRT), and by fractionation scheme, from €1,308 (extreme hypofractionation) to €4,094 (standard fractionation). Accounting for 2023 complexity levels, mean treatment cost rose by 0.9%, but varied widely by tumor site, with a 13% increase for stomach cancer, and decreases of -15.0, -24.4, and - 17.2% in myeloma, pancreas, and lung cancer, respectively. Including complementary examinations and hospital overhead costs, mean cost increased by 15.6%., Conclusion: This study provides a first approximation to EBRT cost using time-driven activity-based costing (TD-ABC) in Catalonia showing the feasibility of the assessment. For each indication, average treatment cost increases with the associated complexity. Additionally, costs decrease with hypofractionation schemes, largely due to lower equipment weight in treatment cost. Consequently, the adoption of stereotactic techniques is driving cost decreases. Overall, this model represents a robust tool for analyzing different possible scenarios, including changes in fractionation and complexity., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Corral, Algara, Muñoz-Montplet, Eraso, Giralt, Defourny, Lievens and Borras.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results